Piper Sandler Reiterates 'Overweight' Rating and $875 Target Price for Regeneron

Piper Sandler analysts have reaffirmed their 'overweight' rating and $875 share price target for biotechnology company Regeneron. The analysts maintain their confidence in the company's long-term growth potential. The strong sales performance of products in the company's portfolio, particularly treatments in ophthalmology and immunology, forms the basis of this optimistic outlook. Progress in Regeneron's R&D pipeline also supports future growth expectations. This reiterated recommendation conveys a message of confidence to market participants that the company's current valuation reflects long-term prospects. The target price indicates a significant potential return opportunity from the stock's current levels. In financial markets, especially within the biotechnology sector, research firms' target price and rating updates can significantly influence investor decisions. Piper Sandler's move may increase institutional interest in Regeneron shares. This is not investment advice.